Heron Therapeutics, Inc. (HRTX) Short Interest Update
Heron Therapeutics, Inc. (NASDAQ:HRTX) was the target of a large decrease in short interest in the month of August. As of August 15th, there was short interest totalling 12,723,565 shares, a decrease of 8.6% from the July 31st total of 13,920,842 shares. Based on an average daily volume of 505,331 shares, the days-to-cover ratio is presently 25.2 days. Currently, 23.9% of the company’s shares are sold short.
A number of research firms have recently weighed in on HRTX. BidaskClub cut Heron Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, August 18th. Cantor Fitzgerald set a $31.00 price target on Heron Therapeutics and gave the stock a “buy” rating in a report on Friday, August 18th. Noble Financial reiterated a “buy” rating on shares of Heron Therapeutics in a report on Thursday, August 10th. Jefferies Group LLC reiterated a “buy” rating on shares of Heron Therapeutics in a report on Wednesday, August 16th. Finally, Cowen and Company set a $40.00 price target on Heron Therapeutics and gave the stock a “buy” rating in a report on Thursday, August 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eleven have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $31.00.
Large investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC purchased a new stake in Heron Therapeutics during the second quarter worth $78,134,000. Tang Capital Management LLC increased its stake in Heron Therapeutics by 39.7% in the first quarter. Tang Capital Management LLC now owns 8,654,914 shares of the biotechnology company’s stock worth $129,824,000 after buying an additional 2,457,716 shares during the period. FMR LLC increased its stake in Heron Therapeutics by 36.7% in the first quarter. FMR LLC now owns 8,030,880 shares of the biotechnology company’s stock worth $120,464,000 after buying an additional 2,158,041 shares during the period. Citadel Advisors LLC increased its stake in Heron Therapeutics by 529.5% in the first quarter. Citadel Advisors LLC now owns 1,283,679 shares of the biotechnology company’s stock worth $19,255,000 after buying an additional 1,079,746 shares during the period. Finally, Broadfin Capital LLC increased its stake in Heron Therapeutics by 26.9% in the first quarter. Broadfin Capital LLC now owns 4,947,403 shares of the biotechnology company’s stock worth $74,211,000 after buying an additional 1,047,816 shares during the period.
Heron Therapeutics (NASDAQ:HRTX) opened at 16.50 on Friday. The company’s 50-day moving average price is $16.13 and its 200-day moving average price is $14.85. Heron Therapeutics has a one year low of $12.21 and a one year high of $20.85.
Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.80) EPS for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.10. The business had revenue of $8.51 million during the quarter, compared to the consensus estimate of $4.53 million. Equities analysts forecast that Heron Therapeutics will post ($3.51) EPS for the current year.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.